Navigation Links
Early Drug Treatment May Cut Multiple Sclerosis Risk
Date:10/6/2009

Improved rates of prevention or delay of full-blown disease seen in treated study patients

TUESDAY, Oct. 6 (HealthDay News) -- Among patients who show early signs of multiple sclerosis, treatment with a drug called glatiramer acetate appears to halve the risk that they will develop full-blown disease, new research suggests.

About 85 percent of patients who are diagnosed with multiple sclerosis first show signs of a "clinical event" that goes away. But many people who have this happen -- about one-third -- don't go on to develop the disease, and most of the rest won't be severely disabled, research has shown.

In the new study, published in Oct. 6 online edition of The Lancet, 481 people who showed possible signs of multiple sclerosis were assigned to receive either a placebo or glatiramer acetate for up to 36 months. The dosage for those who received the active drug was 20 milligrams per day.

The researchers found that glatiramer acetate reduced the risk of developing the disease by 45 percent compared to the placebo, and it took longer for some patients to develop the disease -- it was an average of about two years for those who took the drug compared to about one year for those who didn't.

Injection-related side effects were common: more than half of those who were given glatiramer acetate developed problems around the site of their injections, and about 19 percent had reactions right after receiving the treatment. By comparison, 24 percent of those who were given the placebo had reactions at the site of their injections, and only 5 percent had problems immediately after the treatment, according to the study authors.

"This study establishes glatiramer acetate as an option for patients with clinically isolated syndrome who choose to start treatment early to improve control of the underlying disease process," the researchers concluded.

More information

Learn mor
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Early H1N1 Vaccination Saves Lives, Cuts Costs: Study
2. New Government Research Finds One in Every 100 Children Has Autism, of Whom Nearly 40% Are Recovered
3. Molecular imaging holds promise for early intervention in common uterine cancer
4. A potential new imaging agent for early diagnosis of most serious skin cancer
5. Clearly Contacts Director of Web Sales Named as One of Canada's Top Online Marketers of 2009
6. Training clinicians helps reduce rates of early childhood cavities
7. Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women
8. Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage
9. Switching early breast cancer patients to exemestane improves long-term survival
10. LA County Announces: Nearly 40,000 Seniors and Disabled to Lose Home Care Service Hours Due to State Budget Cuts
11. New device finds early signs of eye disease in preemies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference ... in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has ... are doctors and researchers at the top of their field and will be ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what ... with the Vatican and society is. Yisrayl also provides the meaning of his own name ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , , , SILVER SPRING, ... Wellness Center has selected Artefill, the first and only FDA-approved microsphere-enhanced ... who are looking for a longer lasting dermal filler. Dr. Gonzalez ... to its proven success and effectiveness for the correction of wrinkles. ...
... , , WASHINGTON, Aug. 24 ... Veterans Affairs (VA) is taking steps to assist Veterans seeking compensation ... hidden wounds of war are being addressed vigorously and comprehensively by ... the 21st century," said Secretary Shinseki. , , ...
... , , , , ... the most powerful person in healthcare by readers of Modern ... whose name has become inextricably linked with healthcare reform, topped the ... , , "Think about healthcare reform. Now, try ...
... AUBURN HILLS, Mich., Aug. 24 ... leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable ... collaboration agreement with a major tobacco company for the ... (FSC) cigarettes. FSC cigarettes are designed to meet government ...
... , , , EMERYVILLE, Calif., ... , Inc. (NYSE-Amex: NBY ), a clinical stage ... a wide range of bacterial, viral, and fungal infections, announced today ... the 47th Annual Meeting of the Infectious Diseases Society of America ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
Cached Medicine News:Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Obama Named the Most Powerful Person in Healthcare 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... 4, 2015  Allergan plc (NYSE: AGN ) a ... , CEO and President of Allergan, will provide an overview ... Global Healthcare Conference 2015 in New York, NY ... The presentation will take place on Thursday, September ... Hyatt New York, 109 East 42nd Street, New ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... Expanding its offering of passive safety devices to protect ... Braun Medical Inc. (B. Braun) recently announced that the ... of the company,s Introcan Safety ® 3 Closed ... Safety ® IV Catheter. B. Braun made the ...
... is well known that ophthalmologists around the world often ... (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to ... efficacy. AMD Alliance International (AMDAI) is ... of a concerning surge in eye infections over the ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: